Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data. On September 8, 2014, the Company announced that it is terminating development of DiaPep277 for newly … [Read more...]